Glitamin15 mg+500 mg

Glitamin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, specifically in patients who are not adequately controlled on metformin or pioglitazone monotherapy alone, or in patients already being treated with a combination of pioglitazone and metformin as separate tablets.

• Established use: Type 2 diabetes mellitus, as an adjunct to diet and exercise, when monotherapy with either component fails to provide adequate glycemic control.
• Not indicated for: Type 1 diabetes mellitus or diabetic ketoacidosis.

Glitamin is not a first-line agent for treatment-naive patients and should be initiated only after an inadequate response to single-agent therapy, or as a continuation for patients already stable on both components individually.

Pioglitazone + Metformin Hydrochloride is a fixed-dose combination tablet containing two oral antidiabetic agents:

• Pioglitazone (as pioglitazone hydrochloride) — a thiazolidinedione insulin sensitizer.
• Metformin hydrochloride — a biguanide that reduces hepatic glucose production.

Common fixed-dose strengths include 15 mg/500 mg, 15 mg/850 mg, and other pioglitazone/metformin ratios depending on the manufacturer and market.

Glitamin is a combination oral antidiabetic medicine that brings together a thiazolidinedione (pioglitazone) and a biguanide (metformin hydrochloride) in a single tablet. It is used in adults with type 2 diabetes mellitus to help lower blood glucose levels as part of a comprehensive treatment plan that also includes diet and exercise.

By combining two complementary mechanisms of glucose control, Glitamin allows more patients to reach their glycemic targets with a single, convenient dosing regimen compared with taking each component separately.

Glitamin belongs to the therapeutic class of oral antidiabetic agents (combination therapy), specifically combining a thiazolidinedione (TZD) with a biguanide.

Pioglitazone + Metformin Hydrochloride combines two antihyperglycemic agents with complementary mechanisms of action:

• Pioglitazone is a selective agonist of peroxisome proliferator-activated receptor-gamma (PPAR-γ). Activation of PPAR-γ regulates the transcription of insulin-responsive genes involved in glucose and lipid metabolism, improving peripheral insulin sensitivity in muscle and adipose tissue and reducing hepatic glucose output, without directly stimulating insulin secretion.
• Metformin hydrochloride lowers blood glucose primarily by decreasing hepatic gluconeogenesis, decreasing intestinal absorption of glucose, and improving insulin sensitivity through increased peripheral glucose uptake and utilization. It does not stimulate insulin secretion from the pancreas and therefore does not typically cause hypoglycemia when used alone.

Together, these two mechanisms provide complementary glycemic control by targeting both insulin resistance and hepatic glucose overproduction.

Glitamin should be taken orally, with food, to help reduce gastrointestinal upset. Tablets should be swallowed whole with a glass of water and should not be crushed or chewed unless otherwise directed by a physician. It is important to take Glitamin at the same time(s) each day to maintain consistent blood levels and glycemic control.

Glitamin has several clinically significant drug interactions that require monitoring or dose adjustment:

• Iodinated contrast media: Use of intravascular iodinated contrast agents can lead to acute kidney injury and increase the risk of metformin-associated lactic acidosis. Glitamin should be temporarily discontinued at or before the imaging procedure in patients with reduced kidney function, and withheld for 48 hours after the procedure, restarting only after renal function is confirmed stable.
• Alcohol: Alcohol potentiates the effect of metformin on lactate metabolism and increases the risk of lactic acidosis. Patients should be warned against excessive alcohol intake while taking Glitamin.
• CYP2C8 inhibitors (e.g., gemfibrozil): May significantly increase pioglitazone plasma concentrations; the pioglitazone dose within Glitamin may need to be limited when co-administered with strong CYP2C8 inhibitors.
• CYP2C8 inducers (e.g., rifampin): May decrease pioglitazone plasma concentrations, potentially reducing glycemic control; dose adjustment and closer glucose monitoring may be needed.
• Other antidiabetic agents (insulin, sulfonylureas): Combining Glitamin with insulin or insulin secretagogues increases the risk of hypoglycemia and, with insulin specifically, increases the risk of fluid retention and heart failure; dose reduction of the concomitant agent may be required.
• Cationic drugs (e.g., ranolazine, cimetidine, dolutegravir): May compete with metformin for renal tubular transport, increasing metformin exposure and lactic acidosis risk.

Common and serious side effects have been reported with Glitamin:

Common side effects

• Upper respiratory tract infection
• Gastrointestinal upset (nausea, diarrhea, abdominal discomfort, metallic taste)
• Headache
• Edema (fluid retention)
• Weight gain

Less common but serious side effects

• Vitamin B12 deficiency with long-term use, which may cause or worsen anemia or peripheral neuropathy
• Bone fractures, more commonly reported in female patients
• Macular edema (swelling in the eye) — reported post-marketing
• Hypoglycemia, particularly when combined with insulin or sulfonylureas

Rare but serious side effects

• Lactic acidosis (see Precautions and Warnings for full detail)
• New or worsening heart failure (see Precautions and Warnings)
• Bladder cancer signal with long-term pioglitazone use (see Precautions and Warnings)
• Hepatic failure (rare, post-marketing reports)

Pregnancy: Glitamin should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Poorly controlled diabetes during pregnancy carries significant risks to both mother and fetus. Insulin is generally the preferred agent for glycemic control during pregnancy according to standard obstetric practice, and patients who become pregnant while taking Glitamin should consult their physician promptly to discuss switching to an insulin-based regimen.

Lactation: It is not known whether pioglitazone is present in human breast milk; metformin passes into breast milk in small amounts. Because of the potential for adverse effects in a nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue Glitamin, taking into account the importance of the drug to the mother. Consult a physician before use while breastfeeding.

Lactic Acidosis (Serious Warning)

Metformin, a component of Glitamin, can rarely cause a serious and potentially fatal metabolic complication called lactic acidosis. Risk factors include renal impairment, age 65 years or older, use of iodinated contrast media, surgery, hepatic impairment, dehydration, excessive alcohol intake, and conditions associated with hypoxemia. Symptoms may include malaise, myalgia, respiratory distress, increasing somnolence, and non-specific abdominal distress. If lactic acidosis is suspected, Glitamin should be discontinued immediately and the patient should seek emergency medical care.

Heart Failure and Fluid Retention

Pioglitazone, a component of Glitamin, can cause or worsen congestive heart failure due to dose-related fluid retention, particularly when combined with insulin. Glitamin is contraindicated in patients with established NYHA Class III or IV heart failure. Patients should be monitored for signs and symptoms of heart failure, including excessive rapid weight gain, dyspnea, and edema; if these develop, the condition should be managed according to standard of care, and discontinuation or dose reduction of Glitamin should be considered.

Bladder Cancer

Pioglitazone has been associated with an increased risk of urinary bladder cancer, particularly with longer duration of use and higher cumulative dose. Glitamin should not be used in patients with active bladder cancer, and should be used with caution in patients with a prior history of bladder cancer. Patients should be advised to promptly report any signs of blood in the urine, urinary urgency, pain on urination, or back or abdominal pain.

Hepatotoxicity

Liver function tests should be checked before starting Glitamin and periodically thereafter. Glitamin should not be started in patients with active liver disease or elevated baseline liver enzymes, and should be discontinued if jaundice or significant liver enzyme elevation occurs.

Other Precautions

• Fluid retention may lead to or worsen edema; use with caution in patients with pre-existing edema.
• Ovulation may resume in premenopausal, anovulatory women treated with pioglitazone, with a resulting risk of unintended pregnancy; adequate contraception should be discussed.
• Bone mineral density loss and fracture risk are increased, particularly in women; bone health should be assessed periodically.
• Vitamin B12 levels should be monitored periodically with long-term use.
• Temporary discontinuation is recommended before and after procedures requiring iodinated contrast, and before surgery under general anesthesia.

Overdose of Glitamin may present with severe hypoglycemia (from the combined antidiabetic effect) and/or symptoms of lactic acidosis (malaise, muscle pain, difficulty breathing, drowsiness, abdominal discomfort). Overdose is a medical emergency.

If an overdose of Glitamin is suspected, seek immediate medical attention or contact emergency services / a poison control center right away. Do not attempt to manage a suspected overdose at home. Hospital management may include general supportive care, monitoring of vital signs and blood glucose, and hemodialysis, which can effectively remove metformin and correct the associated lactic acidosis in severe cases.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

Glitamin is contraindicated in patients with an eGFR below 30 mL/min/1.73m², and initiation is not recommended for eGFR between 30-45 mL/min/1.73m². Renal function should be checked before starting and periodically during treatment (see Dosage and Administration).

Hepatic Impairment

Glitamin should be avoided in patients with active liver disease or significantly elevated liver enzymes (see Precautions and Warnings).

Elderly Patients

Elderly patients are at higher risk of renal impairment and lactic acidosis; renal function should be assessed more frequently, and dosing should be conservative, generally not titrating to the maximum dose in patients with reduced renal reserve.

Pediatric Patients

Safety and effectiveness of Glitamin in pediatric patients have not been established; it is not recommended for use in children.

Glitamin is generally used long-term as part of chronic management of type 2 diabetes mellitus, alongside diet and exercise. There is no fixed treatment duration; therapy should continue as long as it remains effective, well-tolerated, and clinically indicated, with regular monitoring of glycemic control (HbA1c), renal function, and liver function. Treatment should not be stopped or changed without consulting a physician.

Combination oral antidiabetic: thiazolidinedione (pioglitazone) plus biguanide (metformin hydrochloride).

Pioglitazone + Metformin Hydrochloride works through two complementary mechanisms: pioglitazone activates PPAR-γ receptors to improve peripheral insulin sensitivity and reduce insulin resistance in muscle and fat tissue, while metformin hydrochloride reduces hepatic glucose production and improves peripheral glucose uptake. Together, these actions lower blood glucose without directly stimulating pancreatic insulin secretion.

The safety and effectiveness of Glitamin in pediatric patients (under 18 years) have not been established. Glitamin is not recommended for use in children, and alternative, pediatric-approved therapies should be considered under specialist guidance.